56 results about "Receptor interaction" patented technology

The invention belongs to the field of bioinformatics, and relates to an improved integrated deep learning cell communication ligand-receptor interaction prediction method. The method comprises the following steps: firstly, carrying out extraction and dimensionality reduction on biological sequence features of a ligand and a receptor, and constructing multi-modal feature input; secondly, constructing an improved deep neural network branch, introducing a batch normalization layer and a Leaky ReLU activation function, solving the problems of gradient disappearance and neuronal necrosis, and improving regularization strength to prevent overfitting; meanwhile, an enhanced heterogeneous graph auto-encoder branch is constructed, the graph embedding dimension is remarkably expanded to improve the feature capacity, and full convergence of the model is ensured by increasing training rounds; thirdly, fusing the improved deep network with the prediction probability of a heterogeneous graph auto-encoder by adopting a weighted integration strategy; and finally, outputting a potential interaction relationship based on the fusion probability. By optimizing the architecture and the strategy, the prediction accuracy and robustness are remarkably improved, and a reliable tool is provided for analyzing a complex cell communication network.

A dynamic antimicrobial hydrogel based on natural receptor-ligand recognition, and a preparation method and use thereof are provided. A ligand vancomycin and a receptor AA-based material each are first modified with a modification material, and then a photoinitiator is added to prepare a hydrogel material under irradiation of ultraviolet (UV) light. In the hydrogel, a three-dimensional (3D) network structure is formed through crosslinking. After undergoing a fracture under an external pressure, the hydrogel can rapidly heal itself through crosslinking due to a ligand-receptor interaction and a multi-hydrogen-bond interaction, which bio-mimicks a natural ligand-receptor interaction to realize the dynamics of the hydrogel material. The high antiomicrobial activity of vancomycin imparts the functionality of the hydrogel material; and the physiologically-derived monomer improves the biocompatibility and reduces the biological toxicity.

The present invention relates to a polymer conjugate comprising a ULA polymer a) and one or more polypeptides b), wherein the polypeptides are conjugated to the ULA polymer, and the conjugate is coated on the surface of a device for culturing cells. The peptides can interact with receptors on the surface of the cells, while the polymer prevents non-specific binding of the cells to the surface of the device.

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Provided are a compound as a receptor-interacting protein (RIP) inhibitor, a preparation method therefor, and a use thereof, relating to the field of chemical medicines. The compound is a compound as represented by formula (I), or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof. The compound has good inhibitory activity on humanized RIP1 kinase, and can be used for preparing drugs for resisting inflammation, resisting tumors and the like.

The application discloses double-gene engineered mesenchymal stem cells and application thereof, relates to the technical field of biological medicine. The double-gene engineered mesenchymal stem cells provided by the application co-express CXCR4 and TNFSF14 proteins, exhibit enhanced tumor tropism and immune-mediated anti-tumor activity. Specifically, based on the principle that CXCR4 can enhance the active homing ability of mesenchymal stem cells to gastric cancer lesions expressing its ligand SDF-1 (SDF-1 / CXCL12), and TNFSF14 (LIGHT) can interact with HVEM and LTbetaR receptors to promote the activation of T cells and NK cells, the mesenchymal stem cells co-expressing CXCR4 and LIGHT overcome the defects of insufficient targeting of natural MSCs and weak immune activation ability, and have excellent anti-tumor effect.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen / immune receptor interactions, in a single-cell format.

The present disclosure provides compounds, including piperazine heterocyclic amide urea compounds (including the corresponding sulfonamides), that inhibit cell necrosis and / or human receptor-interacting protein 1 kinase (RIP1), and pharmaceutically acceptable salts, hydrates, and stereoisomers thereof. The compounds of the present invention are used in pharmaceutical compositions and methods of use and manufacturing, including treating a person in need thereof with an effective amount of a compound or composition of the present invention and detecting a resulting improvement in the person's health or condition.

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine / threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

Antibodies that target VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody-dependent cellular cytotoxicity (ADCC) as well as Antibody Dependent Cellular Phagocytosis (ADCP), and prevent VZV infection of cells.

This invention provides material compositions and / or methods suitable for the prevention and / or treatment of protein depletion (protein deficiency), comprising material compositions that preserve the natural function of peptides / proteins while limiting and / or preventing the formation and / or aggregation of said peptides / proteins into amyloid protein. It also provides material compositions and formulations for enhancing peptide / protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, and promoting peptide / protein synthesis and purification.

The invention discloses an application of sodium bicarbonate in preparation of a tumor immune drug enhancer. The molecular formula of the sodium bicarbonate is NaHCO3. Tumor necrosis factor alpha (TNF-alpha) is used as an anti-tumor drug to treat tumors, however, the anti-tumor efficacy of the TNF-alpha is unpredictable. It is proved that TNF-alpha activates a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells, NF-kappa B) signal channel, inflammatory response is enhanced, tumor cell growth is promoted, and the TNF-alpha can activate a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells (NF-kappa B) signal channel. Under the action of sodium bicarbonate, a TNF-alpha mediated NF-kappa B signal channel is inhibited, a TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) dependent Necroptosis signal channel is activated, and the death of tumor cells is caused, so that the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) depends on the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) and the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1). The prepared medicine contains a medicine excipient or a carrier allowed by a preparation. The invention develops new application of sodium bicarbonate in preparation of medicines for treating tumors. And the medicine is non-toxic to a human body after being administrated in a tumor body. Sodium bicarbonate can be used for preparing a reinforcing agent of TNF-alpha.

A computational framework for high-throughput mapping, validating, and predicting receptor sequence interactions is described. A method includes pre-processing sequence data, adjusting data for noise, generating intermediate strength of interaction data, aggregating the intermediate strength of interaction data based on dextramer clustering and based on TCR clustering, and generating final relative strength of interaction data that identifies reliable TCR-pMHC binding events.

The invention provides an intercellular communication dynamic analysis method and system based on a graph reaction diffusion model, and relates to the field of biological information analys.The method comprises the steps that spatial transcriptome data to be analyzed is obtained, and meanwhile a ligand-receptor reaction database is introduced; constructing a reaction-diffusion partial differential equation set by utilizing a Fick law and a mass action law based on the ligand-receptor reaction database; a graph signal processing method is introduced, cells in space transcriptome data are defined as nodes, a space graph is constructed based on the space neighborhood relation of the cells, a graph Laplacian matrix of the space graph is calculated, a reaction-diffusion partial differential equation set is converted into a graph signal form, numerical solution is carried out, and the response-diffusion partial differential equation set is obtained. Simulating a spatio-temporal evolution process of ligand-receptor interaction to obtain cell-cell communication information depicted by a ligand-receptor reaction intensity matrix; accurate inference of cell-cell communication is realized under various space omics platforms, and the method has relatively high stability, generalizability and biological interpretability.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

The invention relates to the technical field of nano-materials, in particular to a polypeptide nano-material for binding HER2 and a preparation method and application thereof, the polypeptide nano-material comprises polypeptide with an amino acid sequence as shown in SEQ ID NO: 1 and an I-type photosensitizer connected with the last amino acid of the polypeptide; the polypeptide comprises a ligand unit and a fiber deformation element; the I-type photosensitizer is connected to one end, deviating from the ligand unit, of the fiber deformation element, and the I-type photosensitizer has the aggregation-induced emission characteristic. The polypeptide nano-material can be self-assembled in an aqueous solution through hydrophilic and hydrophobic effects to form spherical nano-particles, the spherical nano-particles are disintegrated through ligand-receptor interaction induction, and an ordered, stable and continuous beta-folding structure is formed through a pi-pi accumulation effect and a hydrogen bond, so that the polypeptide nano-material is converted into a nanofiber network structure in situ in a tumor, and the tumor activity is improved. The type and intensity of active oxygen generated by the I-type photosensitizer with AIE characteristics can be remarkably improved, and finally, specific efficient photodynamic therapy of HER2 positive breast cancer is realized.

This invention relates to a self-assembling polypeptide for regulating the permeability of retinal pigment epithelium (RPE), its preparation method, and its applications. The self-assembling polypeptide comprises an integrin receptor-targeting peptide, a self-assembling polypeptide, and a hydrophobic molecule sequentially linked. The self-assembling polypeptide designed in this invention can self-assemble into nanoparticles and specifically target RPE cells. After interacting with receptors on the cell membrane, the nanoparticles transform into nanofibers, achieving rapid targeted enrichment of RPE tissue. Furthermore, by regulating the permeability of RPE tissue, it can enhance the transcellular drug transport capacity, providing a new clinical application strategy for the treatment of macular neovascularization, especially polypoid choroidal vascular lesions.

Provided are a recombinant human fibronectin (FN) having a complex function of soothing, a preparation method therefor, and the use thereof. Said recombinant human fibronectin has an amino acid sequence shown as SEQ ID NO.1. By adding a hyaluronic acid interaction segment of human fibronectin while retaining main segments of human fibronectin cell adhesion and integrin receptor interaction, and linking the two domains by means of a flexible "linker" amino acid sequence GGS, the recombinant human FN protein having the complex function is constructed. While possessing core characteristics of traditional recombinant fibronectins, the present recombinant human fibronectin also exhibits an effect of soothing cell irritations. Therefore, the prepared recombinant human fibronectin is expected to exhibit a good effect in soothing skin irritation in the field of functional active skincare products.

Provided herein are methods, compositions, and kits for treating inflammatory disease, fibrostenotic disease, and / or fibrotic disease by targeting receptor-interacting serine / threonine-protein kinase 2 (RIPK2). Also provided herein are methods of treating inflammatory, fibrotic, or fibrostenotic diseases in a subject with an inhibitor of RIPK2 activity or expression, and methods of selecting a subject with an inflammatory, fibrotic, or fibrostenotic disease for treatment with an inhibitor of RIPK2 activity or expression.

The application provides a method for screening active ingredients capable of activating TAS1R3 receptors, and belongs to the technical field of screening of active ingredients of traditional Chinese medicines. The application establishes a biosensor, and the biosensor detects the current signal after each concentration of compound solution reacts with the TAS1R3 receptor; the dissociation constant K D of the interaction between the compound and the TAS1R3 receptor is calculated according to the linear fitting equation between the common logarithm of the concentration of the compound and the current change, and the compound with the K D value in the range of 10 ‑13 -10 ‑8 M is screened as the active ingredient capable of activating the TAS1R3 receptor. In the application, the interaction dissociation constant K D of the Atractylodes lactone II and the glycyrrhizic acid with the TAS1R3 protein is 3.759*10 ‑8 M and 4.435*10 ‑9 M respectively, and the binding force with the TAS1R3 protein is very strong. Moreover, the Atractylodes lactone II and the glycyrrhizic acid have the function of improving anemia within a certain concentration, and provide a new idea for the screening of candidate compounds with the sweet characteristic and the treatment of anemia or blood deficiency syndrome in traditional Chinese medicines and the research and development of new drugs.

A transkingdom platform for the delivery of therapeutics to target cells. The system maintains the export and uptake functions of Inv while modifying its targeting away from β1 integrin to other proteins expressed on the surface of target eukaryotic cells (i.e., a cell surface protein) or chemical moieties (i.e., a cell surface chemical moiety) expressed on the surface of a target eukaryotic cell by replacing D4 and D5 of Inv with a binding domain from a heterologous protein via genetic engineering. These heterologous proteins could be derived from bacterial, fungal, animal, or viral genomes. This engineering would result in the construction of a chimeric Inv protein in which D1-D3 (i.e., the non-binding domains) are fused in frame to an alternative binding domain derived from a heterologous protein. The alternative binding domain would interact with a different cell surface protein or chemical moiety, which can in some instances be referred to as a receptor, on the surface on the surface of a eukaryotic cell, thereby allowing specific targeting to cells independent of Inv's intrinsic β1 integrin binding.

Disclosed herein are kinase inhibiting compounds, such as receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibiting compounds. The disclosed compounds, pharmaceutical compositions, and / or combinations can be used to treat or prevent a kinase-related disease or disorder, particularly a RIP1-related disease or disorder.

The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

A synthetic peptide construct comprises an amino acid sequence-RLIEDICLPRWGCLWEDD (SEQ ID NO: 2) (also known as “GLYCLOK”), a flexible, hydrophilic glycine-serine (Gly-Ser) linker, and a polypeptide chain between 25 to 70 amino acids in length, which incorporates an albumin-binding moiety with a dissociation constant (Kd) to albumin of less than 20 nanomolar (nM). This construct may include the sequence RLIEDICLPRWGCLWEDD (SEQ. ID NO: 2) within its terminal 25 amino acids. The albumin-binding moiety may be cyclic, with a disulfide bond formed by at least one cysteine residue. The constructs is used as an agonist to modulate receptor interactions in vivo, enhancing therapeutic efficacy and extending circulating half-life in mammals, including humans. The peptides exhibit significant binding to albumin, enhancing bioavailability and therapeutic duration.

This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.

The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof.

Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore Bleeding Time do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and / or prolong bleeding time.

Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3). Also disclosed are conjugates and compositions that include the peptides and / or peptidomimetics, methods for directing a moiety to tumor lymphatic vasculature, methods for imaging tumor lymphatic vasculature, methods for reducing or inhibiting tumor metastasis, methods for reducing the number of tumor lymphatic vessels, methods for treating cancer, methods for treating a disease or disorder associated with a gC1q / p32 receptor biological activity, methods for detecting the presence of a gC1q / p32 receptor, methods for detecting interactions between gC1q / p32 receptors and the presently disclosed conjugates and compositions, methods for delivering the presently disclosed conjugates and compositions to gC1q / p32 receptors, methods for assessing gC1q / p32 receptor levels in cells, methods for identifying subjects having diseases associated with gC1q / p32 receptor biological activities, and methods for screening for compounds that interact with gC1q / p32 receptors.